Core Viewpoint - Generate Biomedicines, Inc. has announced the pricing of its initial public offering (IPO) at $16.00 per share, aiming to raise gross proceeds of $400 million before expenses [1] Group 1: IPO Details - The company is offering 25,000,000 shares of common stock in the IPO [1] - Underwriters have a 30-day option to purchase an additional 3,750,000 shares at the IPO price [1] - Trading on the Nasdaq Global Select Market is expected to commence on February 27, 2026, under the ticker symbol "GENB" [1] Group 2: Financial Management - Goldman Sachs & Co. LLC and Morgan Stanley are serving as joint lead book-running managers for the offering [1] - Other book-running managers include Piper Sandler, Guggenheim Securities, and Cantor [1] Group 3: Regulatory Information - A registration statement for the securities was filed and declared effective by the U.S. Securities and Exchange Commission on February 26, 2026 [1] - The offering is being conducted solely through a prospectus [1]
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering